Silencing One Gene Turns Pancreatic Duct Cells Into Insulin Producers

In a study published in Science Translational Medicine, scientists performed a genetic screen on human pancreatic duct cells and found that loss of the gene ALDH3B2 markedly increased their conversion into insulin-producing, beta-like cells. Normally fewer than one percent of duct cells naturally adopt this phenotype, but silencing ALDH3B2 raised the proportion to roughly 8.5 percent. The modified cells were then grafted into mice with diabetes, resulting in detectable human insulin and a drop in blood glucose to near-normal levels that persisted for six weeks.

This approach differs from existing gene-therapy trials that target muscle cells or rely on lab-grown beta cells, offering a strategy that leverages cells already present in the pancreas. However, because ALDH3B2 functions in many tissues, precise targeting will be essential to avoid off-target effects. The researchers plan to explore both gene-therapy delivery and small-molecule inhibitors to replicate the effect.